Literature DB >> 2757910

Effects of vigabatrin on evoked potentials in dogs.

J C Arezzo1, C E Schroeder, M S Litwak, D L Steward.   

Abstract

1. The purpose of this study was to evaluate possible changes in brain morphology and evoked potentials associated with daily administration of 300 mg kg-1 vigabatrin in dogs. 2. Somatosensory evoked potentials (SEP) and auditory evoked potentials (AEP) were recorded at baseline and weekly for 12 weeks of treatment and every 2 weeks for 17 weeks of recovery. Morphology was assessed immediately after treatment for two treated dogs and after recovery for the remaining five treated and two control dogs. 3. Vigabatrin produced a significant slowing of the central transmission measure of the SEP with no alteration in the AEP. Vigabatrin was associated with microvacuolation in select regions of the brain including the fornix, septum, optic tract, hypothalamus, thalamus and cortex. In addition, some microglial proliferation was noted. 4. Changes in SEP and the microvacuolation fully recovered after 17 weeks of treatment. 5. The study confirms vigabatrin-induced microvacuolation in the dog and suggests these changes are associated with functional slowing of conduction in the somatosensory pathways.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757910      PMCID: PMC1379680          DOI: 10.1111/j.1365-2125.1989.tb03462.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Hexachlorophene-induced changes in central and peripheral myelinated axons of developing and adult rats.

Authors:  J Towfighi; N K Gonatas; L McCree
Journal:  Lab Invest       Date:  1974-12       Impact factor: 5.662

2.  Hexachlorophene encephalopathy.

Authors:  P Lampert; J O'Brien; R Garrett
Journal:  Acta Neuropathol       Date:  1973       Impact factor: 17.088

3.  Demyelination and remyelination in lead neuropathy. Electron microscopic studies.

Authors:  P W Lampert; S S Schochet
Journal:  J Neuropathol Exp Neurol       Date:  1968-10       Impact factor: 3.685

4.  Neurotransmitters and CNS disease. Introduction.

Authors:  L L Iversen
Journal:  Lancet       Date:  1982-10-23       Impact factor: 79.321

5.  Ultrastructural changes in isoniazid-induced brain oedema in the dog.

Authors:  W F Blakemore; A C Palmer; P R Noel
Journal:  J Neurocytol       Date:  1972-10

6.  Hind limb somatosensory evoked potentials in the monkey: the effects of distal axonopathy.

Authors:  J C Arezzo; H H Schaumburg; H G Vaughan; P S Spencer; J Barna
Journal:  Ann Neurol       Date:  1982-07       Impact factor: 10.422

7.  Conduction failure in demyelination: is it inevitable?

Authors:  T A Sears; H Bostock
Journal:  Adv Neurol       Date:  1981

8.  Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy.

Authors:  L Gram; B B Lyon; M Dam
Journal:  Acta Neurol Scand       Date:  1983-07       Impact factor: 3.209

9.  The release of gamma-aminobutyric acid during inhibition in the cat visual cortex.

Authors:  L L Iversen; J F Mitchell; V Srinivasan
Journal:  J Physiol       Date:  1971-01       Impact factor: 5.182

10.  Modification of orientation sensitivity of cat visual cortex neurons by removal of GABA-mediated inhibition.

Authors:  T Tsumoto; W Eckart; O D Creutzfeldt
Journal:  Exp Brain Res       Date:  1979-01-15       Impact factor: 1.972

View more
  6 in total

Review 1.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

2.  In Vivo Detection of CPP-115 Target Engagement in Human Brain.

Authors:  Andrew P Prescot; Steven R Miller; Gary Ingenito; Rebekah S Huber; Douglas G Kondo; Perry F Renshaw
Journal:  Neuropsychopharmacology       Date:  2017-07-25       Impact factor: 7.853

Review 3.  A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors:  J Srinivasan; A Richens
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

4.  Effects of vigabatrin on evoked potentials in epileptic patients.

Authors:  V Cosi; R Callieco; C A Galimberti; R Manni; A Tartara; J Mumford; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 5.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 6.  Place of newer antiepileptic drugs in the treatment of epilepsy.

Authors:  R Kälviäinen; T Keränen; P J Riekkinen
Journal:  Drugs       Date:  1993-12       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.